Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer.

[1]  J. Roh,et al.  2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography as guidance for primary treatment in patients with advanced-stage resectable squamous cell carcinoma of the larynx and hypopharynx. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[2]  S. Larson,et al.  Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  B. Loo,et al.  Metabolic tumor volume as an independent prognostic factor in lymphoma , 2005 .

[4]  Mohamed Allaoua,et al.  Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  W. Wong,et al.  The impact of FDG PET on the management of occult primary head and neck tumours. , 2003, Clinical oncology (Royal College of Radiologists (Great Britain)).

[6]  Bong-Jae Lee,et al.  Prediction of prognosis using standardized uptake value of 2-[(18)F] fluoro-2-deoxy-d-glucose positron emission tomography for nasopharyngeal carcinomas. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  Quynh-Thu Le,et al.  Metabolic tumor burden predicts for disease progression and death in lung cancer. , 2007, International journal of radiation oncology, biology, physics.

[8]  Yoshimi Anzai,et al.  FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. , 2005, International journal of radiation oncology, biology, physics.

[9]  C. Grau,et al.  Prospective study of 18FDG‐PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor. Results from the DAHANCA‐13 study , 2008, Head & neck.

[10]  L. Rybicki,et al.  Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R L Wahl,et al.  Squamous Cell Carcinoma of the Head and Neck , 2006 .

[12]  J. Ensley,et al.  An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Cyrill Burger,et al.  Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. , 2003, International journal of radiation oncology, biology, physics.

[14]  H. Minn,et al.  Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  M Schwaiger,et al.  Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  Heikki Joensuu,et al.  Florodeoxyglucose imaging: A method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors , 1988 .

[17]  K. Chao,et al.  Carcinoma of the tonsillar fossa: prognostic factors and long-term therapy outcome. , 1998, International journal of radiation oncology, biology, physics.

[18]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.

[19]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[20]  R. Tucker,et al.  Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on patient management: first year's experience in a clinical center. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Paul Kinahan,et al.  Co-registered FDG-PET/CT imaging for staging and IMRT treatment planning for squamous cell carcinoma of the head and neck , 2003 .

[22]  F. Hoebers,et al.  Tumor Volume as Outcome Predictor in Chemoradiation for Advanced Head and Neck Cancer , 2007 .

[23]  Mithat Gonen,et al.  Diagnostic and Prognostic Value of [18F]Fluorodeoxyglucose Positron Emission Tomography for Recurrent Head and Neck Squamous Cell Carcinoma , 2002 .

[24]  G van Kaick,et al.  Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  M. Piert,et al.  Correlation Between Pretreatment FDG PET Biological Target Volume (BTV) and Anatomical Location of Failure After Radiation Therapy (RT) for Head and Neck Cancers (HNC) , 2007 .

[26]  Mohamed Allaoua,et al.  Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. , 2004, International journal of radiation oncology, biology, physics.

[27]  C. Grau,et al.  Squamous Cell Carcinoma of the Oropharynx-An Analysis of Treatment Results in 289 Consecutive Patients , 2000, Acta oncologica.

[28]  B. Campbell,et al.  Clinical outcomes of patients receiving integrated PET/CT-guided radiotherapy for head and neck carcinoma. , 2008, International journal of radiation oncology, biology, physics.

[29]  Billy W. Loo,et al.  RT_Image: An Open-Source Tool for Investigating PET in Radiation Oncology , 2007, Technology in cancer research & treatment.